Introduction
============

The incidence of oropharyngeal squamous cell carcinoma (OPSCC) has been steadily increasing in the United States and Western Europe, accompanied by a rise in the number of patients with human papillomavirus (HPV)-related OPSCC \[[@b1-roj-2017-00465],[@b2-roj-2017-00465]\]. Patients with HPV-related OPSCC tend to be relatively young and less exposed to tobacco smoking and alcohol \[[@b3-roj-2017-00465]\]. HPV-related OPSCC is now well recognized as a distinct entity presenting with more extensive nodal disease but a better prognosis than HPV-unrelated OPSCC \[[@b4-roj-2017-00465]-[@b6-roj-2017-00465]\]. As the 7th edition of the American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) TNM staging system for traditional OPSCC does not accurately reflect the prognosis of HPV-related OPSCC, there have been several attempts to propose a new prognostic classification. The International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S) study group proposed a novel prognostic classification for HPV-related OPSCC based on the outcome of over 1,900 patients treated in five North American and two European centers \[[@b7-roj-2017-00465]\], which were adopted by the 8th edition of the AJCC/UICC (8th AJCC/UICC) staging system. Previously, because N1 to N2b stages showed similar overall survival (OS) rates, they were reassigned to N1, and traditional N2c, bilateral or contralateral nodes, is now N2. The TNM stages were classified as follows according to clinical outcomes: T1-T2 N0-N1 for stage I, T3 or N2 for stage II, T4 or N3 for stage III, and stage IV reserved for distant metastases.

Because the ICON-S study was based on Western data, it is necessary to evaluate its applicability to patients in other geographic areas. Several Japanese validation studies evaluated the prognostic value of the 8th AJCC/UICC staging system, but somewhat inconsistent results were reported \[[@b8-roj-2017-00465],[@b9-roj-2017-00465]\]. Sano et al. \[[@b8-roj-2017-00465]\] could not find any predictive value of the 8th AJCC/UICC staging system, and Mizumachi et al. \[[@b9-roj-2017-00465]\] reported that there was a significant difference in the 3-year OS rates between stage I-II and III patients, but not between stage I and II. Additionally, applicability of the 8th AJCC/UICC staging system in Korea is still unclear.

Therefore, the first aim of our study was to assess whether the 8th AJCC/UICC staging system could distinguish prognostic groups in patients with HPV-related OPSCC who were treated at a single center in Korea. The second aim was to investigate whether there is a more reflective classification for better prognostic stratification.

Materials and Methods
=====================

1. Patients
-----------

We retrospectively reviewed the medical records of patients diagnosed with non-metastatic OPSCC between January 2010 and December 2016 at our institution. All patients were staged according to the 8th AJCC/UICC TNM staging system using physical and endoscopic exams, computed tomography (CT), magnetic resonance imaging (MRI), and 18F-fluorodeoxyglucose positron emission tomography (PET)/CT imaging. Patients with a history of another malignancy, radiotherapy (RT) for head and neck lesions, or chemotherapy were excluded from this analysis. The protocol was reviewed and approved by the Institutional Review Board of Asan Medical Center, Korea. Identifying number is 2017-1106.

2. Evaluation of HPV status
---------------------------

Two methods are mainly used to evaluate HPV infection status in our institution. One is tumor p16 immunohistochemical (IHC) analysis using CINtec p16 histology (anti-p16^INK4a^ mouse monoclonal antibody and IHC detection kit; Roche MTM Laboratories, Heidelberg, Germany). A positive p16 result was defined as diffuse strong staining in the cytoplasm and nucleus. Focal or faint reactivity was considered negative for p16. The other method is tumor HPV DNA detection by polymerase chain reaction (PCR)/DNA chip scanning, which can detect 43 subtypes of HPV (high-risk subtypes of 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82, and other lower or undetermined risk subtypes). HPV-related OPSCC was diagnosed when either p16 or HPV DNA PCR results were positive.

3. Treatment and follow-up
--------------------------

Patients received either upfront surgery or definitive chemoradiotherapy. Initial decision to perform surgery was made by a surgeon. As a radical surgery, wide excision of the primary tumor with modified radical or selective neck dissection of the lymph nodes on the involved or suspected side of the neck was performed. Postoperative radiotherapy was recommended for patients who had adverse feature in pathologic report: positive surgical resection margin, pathologic T3, or node positive disease. Adjuvant chemotherapy was performed when an advanced nodal stage or extracapsular extension (ECE) was identified in pathologic reports. Concurrent chemoradiotherapy included cisplatin-based (100 mg/m^2^ every 3 weeks) chemotherapy. RT was delivered 5 days per week with intensity-modulated RT or volumetric modulated arc therapy. A total dose of RT was approximately 60--65 Gy at 1.8--2.0 Gy per fraction in the postoperative setting and approximately 70 Gy at 2.0--2.2 Gy per fraction in the definitive setting.

After treatment, the first follow-up was conducted a month after definitive RT or within 6 months after surgery using CT, MRI, and/or PET/CT. Patients were then followed up at least twice a year for physical examinations and at least once a year for imaging.

4. Statistical analysis
-----------------------

Chi-square tests were used to compare categorical variables. The primary endpoint was OS, which was calculated from the date of diagnosis to either death from any cause or the last date on which the patient was known to be alive. The Kaplan-Meier method and Wilcoxon log-rank test were used for survival analysis. For univariate and multivariate analysis, Cox proportional hazards models were used. The hazard ratios, 95% confidence intervals, and p-values were calculated. A p-value of \<0.05 was considered statistically significant. SPSS ver. 22 (IBM SPSS, Armonk, NY, USA) was used for all statistical analyses.

Results
=======

1. Patient characteristics
--------------------------

Between January 2010 and December 2016, 383 patients with OPSCC were diagnosed at our institution. Of these, p16 testing or HPV DNA PCR was performed in 264 patients, and 211 were identified as having HPV-related OPSCC. Twenty-seven patients were excluded: 18 who were not followed up at our institution, 3 who had initially metastatic or recurrent disease, and 6 who had a history of another malignancy. Finally, 184 patients were included in this analysis and their characteristics are shown in [Table 1](#t1-roj-2017-00465){ref-type="table"}. The median age of the patients was 56 years (range, 31 to 81 years), and most patients were men (84%). Fifty-eight patients (32%) had a smoking history of over 20 pack-years. The palatine tonsil was the most common primary site (148 patients, 80%), and there were 22 (12%) cancers of the base of the tongue, 2 (1%) soft palate cancers, and 12 (7%) metastatic neck lymph nodes with an unknown primary site. The proportions of moderately and poorly differentiated squamous cell carcinoma were similar. The HPV-related OPSCC was stage I in 134 (73%), stage II in 23 (13%), and stage III in 27 (15%) patients based on the 8th AJCC/UICC staging system. Upfront radical surgery was performed in 112 patients (61%).

2. The 8th AJCC/UICC staging and survival
-----------------------------------------

The median follow-up time was 38 months (range, 5 to 88 months). The 3-year and 5-year OS rates for all patients were 91.3% and 86.5%, respectively. In the T category of the 8th AJCC/UICC staging, relatively good prognostic stratification was observed (overall p = 0.024) ([Fig. 1A](#f1-roj-2017-00465){ref-type="fig"}). T4 disease showed a worse survival than T1 (p = 0.002) and there was a marginally significant difference between T1 and T2 disease (p = 0.085) and between T2 and T4 disease (p = 0.060). After adjusted by age, T4 disease was still showed a significantly worse survival than T1 and T2 disease (p = 0.009 and p = 0.039, respectively). On the contrary, the N category of the 8th AJCC/UICC staging could not distinguish the prognoses in N0 through N3 disease (overall p = 0.243) ([Fig. 1B](#f1-roj-2017-00465){ref-type="fig"}). The 3-year OS rates for patients with stage I, II, and III disease were 94.4%, 86.2%, and 78.4%, respectively ([Fig. 1C](#f1-roj-2017-00465){ref-type="fig"}). There was a significant difference in OS between stage I and III (p = 0.005), but stage II was not significantly different from stage I or III (p = 0.470 and p = 0.209, respectively).

Univariate and multivariate analyses of prognostic factors for OS were performed ([Table 2](#t2-roj-2017-00465){ref-type="table"}). Age \>56 years and the 8th AJCC/UICC stage were the only significant prognostic factors in univariate analysis (p = 0.044 and p = 0.027, respectively), the prognostic impact of which was retained in the multivariate analysis (p = 0.022 and p = 0.011, respectively). Other clinical factors including smoking and alcohol history, primary site, histology, ECE, primary treatment, and chemotherapy were not significant prognostic factors for OS.

In a subgroup analysis of patients aged ≤56 or \>56 years, there was no difference in OS according to the 8th AJCC/UICC staging in the younger patients of 56 years or less (overall p = 0.313). The difference in OS between stage I and III was observed in patients older than 56 years (p = 0.003), stage II still was not significantly different from stage I or III in older age group (p = 0.155 and p = 0.133, respectively).

3. Refining prognostic classification
-------------------------------------

Because intersection of survival curves of stage I and II was observed and more patients were assigned to stage I than stage II and III, we tried to divide stage I into the following two groups: T0-1 N0-1 and T2 N0-1. This separation showed that the T2 N0-1 and stage II patients had similar survival rates ([Fig. 2A](#f2-roj-2017-00465){ref-type="fig"}). Accordingly, we reclassified the prognostic group of the 8th AJCC/UICC staging as follows: T0-1 N0-1 as group A, T2-3 or N2 as group B, and T4 or N3 as group C ([Fig. 3](#f3-roj-2017-00465){ref-type="fig"}). The 3-year OS rates of refined groups A, B, and C were 98%, 91%, and 78%, respectively, and this refined staging showed better prognostic stratification than the 8th AJCC/UICC staging (overall p = 0.004) ([Fig. 2B](#f2-roj-2017-00465){ref-type="fig"}).

In a multivariate analysis for OS that included refined stage instead of the 8th AJCC/UICC stage, refined stage was still an independent prognostic factor (overall p = 0.009), although the distinction of the adjusted hazard ratio between groups A and B became statistically less significant (adjusted hazard ratio for group B to group A = 5.386; p = 0.107).

In a subgroup analysis, there was no difference in OS according to the refined staging in the younger patients under 56 years of age (overall p = 0.320) ([Fig. 4A](#f4-roj-2017-00465){ref-type="fig"}), but the difference in OS according to the refined group became clear in patients over 56 years of age (overall p = 0.003) ([Fig. 4B](#f4-roj-2017-00465){ref-type="fig"}). In older age group, statistical significance of the difference in OS between Group B and other groups was higher than the 8th AJCC/UICC staging (p = 0.081 for group B vs. A; p = 0.012 for group B vs. C).

Discussion and Conclusion
=========================

As previously reported in several studies \[[@b4-roj-2017-00465],[@b10-roj-2017-00465],[@b11-roj-2017-00465]\], the present study also confirmed a favorable outcome of HPV-related OPSCC, reporting 3-year and 5-year OS rates for all patients of 91.3% and 86.5%, respectively. Nodal status is known to have less influence on prognosis despite a relatively extensive nodal spread at presentation. Although the ICON-S study group distinguished between N0 and N1 (ipsilateral lymph node involvement), because there was no difference in survival between the two groups, they were classified into the same prognostic group. The present study also did not find a difference in survival between N0 and N1 groups. In contrast, the T category showed a relatively better prognostic stratification in this case series.

In the present study, stage II did not show a significant survival difference from stage I or III. Similar results were obtained in a validation study conducted in Japan \[[@b9-roj-2017-00465]\]. The authors evaluated 111 patients with p16 positive OPSCC treated at a single institution in Japan. The 3-year OS rate of stage III was 70.2%, which is significantly lower than stage I and II. But, the 3-year OS rates of stage I and II were the same at 90.9%. The ICON-S study group also showed excellent prognostic stratification according to the 8th AJCC/UICC staging in both training and validation cohort. But the survival curve of stage II was located closer to that of stage I than stage III, with a relatively small difference between the survival curves of stage I and II compared with the difference between those of stages II and III. These similar results suggest that there is room for increasing the prognostic value of TNM classification by modifying the definition of stage II.

In HPV-related OPSCC, the T stages were more influential in the survival outcome than the N stages. Therefore, dividing stage I into T1 and T2 groups is considered a reasonable approach. After we classified the T2 N0-1 group as stage II, the survival analysis with the refined grouping showed a clearer separation of stage II from the other stages.

Our univariate and multivariate analyses revealed that age ≤56 years is the only independent prognostic factor except TNM classification. The fact that age is one of the important prognostic factors has also been shown in previous studies evaluating the clinical outcome of HPV-related OPSCC \[[@b4-roj-2017-00465],[@b7-roj-2017-00465],[@b8-roj-2017-00465]\]. The present study shows that the difference in survival rate according to refined staging is mainly observed in patients older than 56 years of age. In patients younger than 56 years, there are no significant differences in survival rates between stages I, II, and even III. Younger age may act as an independent prognostic factor, diluting the difference in survival rates due to stage. We could not find definite evidence of any difference in patient- or treatment-related factors that affect survival between young and old patient groups. Despite inferior survival in elderly patients, Dave et al. \[[@b12-roj-2017-00465]\] reported a favorable survival outcome for patients older than 65 years with a high tolerability for treatment and insisted that elderly patients should be considered for stage-appropriate care.

Clinical factors other than age did not significantly affect the prognosis of HPV-related OPSCC. The 8th AJCC/UICC TNM staging system introduced the use of ECE in the N category but not for HPV-related OPSCC. Several conflicting results have been reported on prognostic impact of ECE \[[@b13-roj-2017-00465]-[@b15-roj-2017-00465]\]. In the present study, we could not find any prognostic value of ECE. Because determination of ECE was based on radiologic findings, accuracy would be reduced. Also, biased result might be derived because pathologically confirmed ECE was indication of concurrent chemotherapy in postoperative setting. However, considering that the degree of lymph node metastasis in the HPV-related OPSCC has a relatively small impact on prognosis, ECE might also be less influential on survival than other malignancies. Further studies on the impact of ECE on prognosis are warranted.

The limitations of this study include its retrospective nature based in a single institution and a lack of treatment standardization. Furthermore, unlike the TNM/UICC staging system using immunohistochemistry for p16 overexpression, p16 and HPV DNA tests were used to classify HPV-mediated OPSCC in the present study. There was only one case of p16-positive/HPV DNA-negative OPSCC, but 23 patients had p16-negative/HPV DNA-positive OPSCC. It is not yet clear whether the prognosis of patients with these inconsistent results for p16 and HPV DNA will differ.

In conclusion, stage II in the 8th AJCC/UICC TNM staging system did not clearly distinguish the prognosis from other stages, and inclusion of the T2N0-1 group in stage II instead of stage I could improve prognostic stratification. Age was independent prognostic factor for HPV-related OPSCC and survival differences according to refined stage are mainly present in older patients.
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###### 

Patient characteristics (n = 184)

  Characteristic                                                                    Value
  --------------------------------------------------------------------------------- -------------
  Age (yr)                                                                          56 (31--81)
  Sex                                                                               
   Male                                                                             154 (84)
   Female                                                                           30 (16)
  ECOG performance status                                                           
   0--1                                                                             179 (97)
   2--3                                                                             5 (3)
  Alcohol (standard drinks/week)^[a)](#tfn1-roj-2017-00465){ref-type="table-fn"}^   
   ≤10                                                                              148 (80)
   \>10                                                                             36 (20)
  Smoking pack-years                                                                
   Never smoker                                                                     67 (36)
   ≤10                                                                              31 (17)
   ≤20                                                                              28 (15)
   \>20                                                                             58 (32)
  Primary site                                                                      
   Palatine tonsil                                                                  148 (80)
   Base of tongue                                                                   22 (12)
   Soft palate                                                                      2 (1)
   Metastatic neck lymph nodes with unknown primary                                 12 (7)
  Histology                                                                         
   SCC, WD                                                                          2 (1)
   SCC, MD                                                                          98 (53)
   SCC, PD                                                                          81 (44)
   Others                                                                           3 (2)
  Clinical T-stage (8th AJCC/UICC)                                                  
   0                                                                                12 (7)
   1                                                                                53 (29)
   2                                                                                88 (48)
   3                                                                                9 (5)
   4                                                                                22 (12)
  Clinical N-stage (8th AJCC/UICC)                                                  
   0                                                                                23 (13)
   1                                                                                131 (71)
   2                                                                                25 (14)
   3                                                                                5 (3)
  Stage (8th AJCC/UICC)                                                             
   I                                                                                134 (73)
   II                                                                               23 (13)
   III                                                                              27 (15)
  Primary treatment                                                                 
   Surgery                                                                          112 (61)
   Radiation                                                                        72 (39)

Values are presented as median (range) or number (%).

ECOG, Eastern Cooperative Oncology Group; SCC, squamous cell carcinoma; WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated; 8th AJCC/UICC, American Joint Committee on Cancer/Union for International Cancer Control staging 8th edition.

A standard drink is any drink that contains approximately 14 g of pure alcohol.

###### 

Comparison of overall survival by clinical factors

  Variable                                                                          Univariate analysis     Multivariate analysis                                                            
  --------------------------------------------------------------------------------- ----------------------- -------------------------------------------------------- ----------------------- --------------------------------------------------------
  Age (yr)                                                                                                                                                                                   
   ≤56 (n = 95)                                                                     Reference                                                                        Reference               
   \>56 (n = 89)                                                                    2.712 (1.028--7.150)    0.044^[\*](#tfn3-roj-2017-00465){ref-type="table-fn"}^   3.183 (1.186--8.542)    0.022^[\*](#tfn3-roj-2017-00465){ref-type="table-fn"}^
  Sex                                                                                                                                                                                        
   Male (n = 154)                                                                   Reference                                                                                                
   Female (n = 30)                                                                  0.572 (0.132--2.478)    0.455                                                                            
  Alcohol (standard drinks/week)^[a)](#tfn2-roj-2017-00465){ref-type="table-fn"}^                                                                                                            
   ≤10 (n = 148)                                                                    Reference                                                                                                
   \>10 (n = 36)                                                                    1.005 (0.333--3.030)    0.993                                                                            
  Smoking pack-years                                                                                                                                                                         
   ≤10 (n = 98)                                                                     Reference                                                                                                
   \>10 (n = 86)                                                                    1.523 (0.612--3.788)    0.365                                                                            
  Subsite                                                                                                   0.947                                                                            
   Palatine tonsil (n = 148)                                                        Reference                                                                                                
   Base of tongue (n = 22)                                                          1.461 (0.423--5.051)    0.549                                                                            
   Soft palate (n = 2)                                                              0.000                   0.984                                                                            
   Neck lymph nodes (n = 12)                                                        0.987 (0.130--7.491)    0.990                                                                            
  Histology                                                                                                 0.492                                                                            
   SCC, WD (n = 2)                                                                  5.080 (0.638--40.438)   0.125                                                                            
   SCC, MD (n = 98)                                                                 Reference                                                                                                
   SCC, PD (n = 81)                                                                 1.061 (0.421--2.677)    0.900                                                                            
   Others (n = 3)                                                                   0.000                   0.982                                                                            
  Clinical ECE                                                                                                                                                                               
   No (n = 155)                                                                     Reference                                                                                                
   Yes (n = 29)                                                                     1.331 (0.441--4.011)    0.612                                                                            
  Primary treatment                                                                                                                                                                          
   Surgery (n = 112)                                                                Reference                                                                                                
   Radiation therapy (n = 72)                                                       0.758 (0.308--1.869)    0.548                                                                            
  Chemotherapy                                                                                                                                                                               
   No (n = 78)                                                                      Reference                                                                                                
   Yes (n = 106)                                                                    0.828 (0.332--2.069)    0.687                                                                            
  Stage (8th AJCC/UICC)                                                                                     0.027^[\*](#tfn3-roj-2017-00465){ref-type="table-fn"}^                           0.011^[\*](#tfn3-roj-2017-00465){ref-type="table-fn"}^
   I (n = 134)                                                                      Reference                                                                        Reference               
   II (n = 23)                                                                      1.651 (0.453--6.014)    0.447                                                    1.596 (0.438--5.812)    0.479
   III (n = 27)                                                                     4.017 (1.456--11.083)   0.007^[\*](#tfn3-roj-2017-00465){ref-type="table-fn"}^   4.860 (1.729--13.665)   0.003^[\*](#tfn3-roj-2017-00465){ref-type="table-fn"}^

HR, hazard ratio; CI, confidence interval; SCC, squamous cell carcinoma; WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated; ECE, extracapsular extension; 8th AJCC/UICC, American Joint Committee on Cancer/Union for International Cancer Control staging 8th edition.

A standard drink is any drink that contains approximately 14 g of pure alcohol.

p \< 0.05.
